Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine
Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial
Sponsor: Health Institutes of Turkey
A PHASE3 clinical study on Covid19, this trial is completed. The trial is conducted by Health Institutes of Turkey and has accumulated 10 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Mar 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Mar 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE3
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Health Institutes of Turkey
For direct contact, visit the study record on ClinicalTrials.gov .